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Cellular Biology
Adiponectin Inhibits Tumor Necrosis Factor-α–Induced
Vascular Inflammatory Response via Caveolin-Mediated
Ceramidase Recruitment and Activation
Yajing Wang, Xiaoliang Wang, Wayne Bond Lau, Yuexing Yuan, David Booth, Jing-Jing Li,
Rosario Scalia, Kyle Preston, Erhe Gao, Walter Koch, Xin-Liang Ma

Rationale: Anti-inflammatory and vascular protective actions of adiponectin are well recognized. However, many
fundamental questions remain unanswered.

Objective: The current study attempted to identify the adiponectin receptor subtype responsible for adiponectin’s
vascular protective action and investigate the role of ceramidase activation in adiponectin anti-inflammatory
signaling.
Methods and Results: Adiponectin significantly reduced tumor necrosis factor (TNF)α–induced intercellular
adhesion molecule-1 expression and attenuated TNFα-induced oxidative/nitrative stress in human umbilical vein
endothelial cells. These anti-inflammatory actions were virtually abolished by adiponectin receptor 1 (AdipoR1-),
but not AdipoR2-, knockdown (KD). Treatment with adiponectin significantly increased neutral ceramidase
(nCDase) activity (3.7-fold; P<0.01). AdipoR1-KD markedly reduced globular adiponectin–induced nCDase
activation, whereas AdipoR2-KD only slightly reduced. More importantly, small interfering RNA-mediated
nCDase-KD markedly blocked the effect of adiponectin on TNFα-induced intercellular adhesion molecule-1
expression. AMP-activated protein kinase-KD failed to block adiponectin-induced nCDase activation and
modestly inhibited adiponectin anti-inflammatory effect. In contrast, in caveolin-1 KD (Cav1-KD) cells, >87% of
adiponectin-induced nCDase activation was lost. Whereas adiponectin treatment failed to inhibit TNFα-induced
intercellular adhesion molecule-1 expression, treatment with sphingosine-1-phosphate or SEW (sphingosine-1phosphate receptor agonist) remained effective in Cav1-KD cells. AdipoR1 and Cav1 colocalized and coprecipitated
in human umbilical vein endothelial cells. Adiponectin treatment did not affect this interaction. There is weak
basal Cav1/nCDase interaction, which significantly increased after adiponectin treatment. Knockout of AdipoR1
or Cav1 abolished the inhibitory effect of adiponectin on leukocyte rolling and adhesion in vivo.
Conclusions: These results demonstrate for the first time that adiponectin inhibits TNFα-induced inflammatory
response via Cav1-mediated ceramidase recruitment and activation in an AdipoR1-dependent fashion.   (Circ Res.
2014;114:792-805.)
Key Words: adipokines
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ardiovascular complications are the leading cause of
death for patients with type 2 diabetes mellitus, a disease affecting >20 million people in the United States.1 The
inflammatory response associated with diabetes mellitus
and the resultant vascular injury initiate more severe diabetic cardiovascular complications, including atherosclerosis
and ischemic heart disease.2 Defining the mechanisms leading to inflammatory vascular injury in diabetes mellitus and

■

sphingolipids

■

vascular system injuries

identifying novel therapeutic strategies capable of protecting
vascular function are therefore in great need.
Adiponectin is an adipocyte-derived cytokine. In contrast to the majority of adipokines (eg, tumor necrosis factor [TNF]-α), which are proinflammatory and significantly
increased in patients with diabetes mellitus, adiponectin is a
potent vascular protective molecule that is markedly reduced
in patients with type 2 diabetes mellitus.3–5 Adiponectin
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Nonstandard Abbreviations and Acronyms
AdipoR1
AdipoR2
AMPK
Cav1
fAPN
gAPN
HUVEC
ICAM-1
KD
KO
nCDase
siRNA
TNF

adiponectin receptor 1
adiponectin receptor 2
AMP-activated protein kinase
caveolin-1
full-length adiponectin
globular adiponectin
human umbilical vein endothelial cells
intercellular adhesion molecule-1
knockdown
knockout
neutral ceramidase
small interfering RNA
tumor necrosis factor

reduces oxidative/nitrative stress, protects endothelial cells
from apoptosis, inhibits leukocyte–endothelial interaction,
and decreases smooth muscle proliferation.6 Two adiponectin
receptors (AdipoR1 and AdipoR2) have been cloned.7 They
belong to a new family of membrane receptors (the progestin
and adiponectin, C1Q and collagen domain-containing receptor superfamily)8–10 predicted to contain 7 transmembrane domains but are topologically distinct from G protein coupled
receptor. Although both AdipoR1 and AdipoR2 are expressed
in vascular endothelial cells, their roles in adiponectin-mediated anti-inflammatory and vascular protective actions have
not been clarified.
Vasodilatory and vascular protective effects of adiponectin have been attributed previously to AMP-activated
protein kinase (AMPK)–mediated endothelial nitric oxide
synthase phosphorylation and nitric oxide production.11,12
However, we recently demonstrated that in the ischemic/
reperfused heart, adiponectin’s antioxidative/antinitrative
effects are largely AMPK independent.13,14 Moreover, a recent study demonstrates that adiponectin activates neutral
ceramidase (nCDase) in an adiponectin receptor–dependent
but AMPK-independent fashion.15 As ceramidase is a key
enzyme converting ceramide, a proinflammatory molecule,
to sphingosine-1-phosphate (S1P), an anti-inflammatory and
cardiovascular protective molecule,16–20 it is possible that adiponectin’s anti-inflammatory and vascular protective effect is
mediated by ceramidase activation. However, direct evidence
supporting this attractive notion is currently lacking.
Therefore, the aims of the current study were to (1) identify the adiponectin receptor subtype responsible for vascular
protective action; (2) determine the role of ceramidase activation in adiponectin-mediated anti-inflammatory signaling;
and (3) investigate whether AdipoR1 functions as a ceramidase or mediates ceramidase activation through other signaling molecules.

Methods
Cell Culture and Treatments

Human umbilical vein endothelial cells (HUVECs; passage 2–3)
were plated on 6-well plates and cultured in endothelial growth medium containing 10% fatal bovine serum, 2 mmol/L glutamine, 100
U/mL penicillin, and 100 μg/mL streptomycin at 37°C and 5% CO2.

On 80% confluence, cells were treated with vehicle, globular adiponectin (gAPN; 2 μg/mL)14 or full-length adiponectin (fAPN; 10 μg/
mL). One hour after adiponectin treatment, 10 ng/mL recombinant
human TNFα protein21 was added. Cells were collected 12 hours after
TNFα treatment and oxidative/nitrative stress and intercellular adhesion molecule-1 (ICAM-1) expression were determined as described
in detail below.

Small Interfering RNA Transfection, Plasmid
Construction, and Transfection

Small interfering RNA (siRNA) duplexes against Cav1,22 AdipoR1,23
AdipoR2,23 AMPKα1,23 and nCDase24 were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). Universal control oligonucleotides (AllStars) from Santa Cruz served as negative control.
HUVECs (80% confluent) were transfected via siIMPORTER siRNA
transfection kit (Qiagen Science Inc, Benelux) per manufacturer’s
protocol (final siRNA concentration: 50 nmol/L).

Ceramidase Enzyme Activity Assay

The nCDase enzyme activity was determined as previously reported,
with minor modification.25 Briefly, at experiment conclusion, cells
were collected and washed twice with PBS. Cell pellets were resuspended in 100-μL 0.25-mol/L sucrose solution, sonicated, and centrifuged at 15 000g for 3 minutes. The supernatant was collected and
protein concentration was determined. A 25-μL sample containing
identical protein amount, 75-μL 25-mmol/L phosphate buffer (pH
7.4), and 0.5-μL 4-mmol/L Rbm14-12 substrate solution in ethanol
(final substrate concentration 40 μmol/L; final ethanol concentration
1%) were loaded into each well of a 96-well plate. The same incubation mixture without supernatant served as negative control. The plate
was incubated at 37°C for 1 hour without agitation. The enzymatic
reaction was stopped by adding 25-μL methanol and 100-μL NaIO4
(2.5 mg/mL) in 200-mmol/L glycine/NaOH buffer (pH 10.6) to each
well. The plate was placed in a dark room for 1 hour. Fluorescent intensity was quantified via SpectraMax Microplate Reader (Molecular
Devices, λex 355 nm, λem 446 nm).

Determination of Superoxide and
Peroxynitrite Content

Superoxide content was quantified by lucigenin enhanced luminescence, and the cellular origin of reactive oxygen species was determined by dihydroethidium staining (Molecular Probes, Carlsbad,
CA) as previously described.26 Nitrotyrosine content, the footprint
of peroxynitrite formation, was quantified by ELISA as previously
described.26,27

Confocal Immunofluorescence Microscopy

Thirty minutes after vehicle or gAPN treatment, HUVECs were fixed
with 4% paraformaldehyde/PBS in μ-Slide (ibidi LLC, Verona, WI)
for 15 minutes followed by PBS washing. Cells were first treated with
antibodies against AdipoR1, caveolin-1 (Cav1), or nCDase, followed
by incubation with tetramethyl rhodamine–conjugated antirabbit IgG
and Cy5-conjugated antigoat IgG. For ceramide and S1P staining,
cells were fixed with 4% paraformaldehyde/PBA for 2 minutes. Cells
were then washed with ddH2O (2 minutes) and TBS (pH 7.6; 5 minutes). The primary antibodies were prepared with TBS solution containing 5 μmol/L of CaCl2 and cells were incubated with antibody
for 2 hours at room temperature. After 10-minute washing with TBS
under agitation, cells were incubated with florescence-labeled secondary antibody. Slides were visualized by a FV1000 confocal microscope with ×60 oil-immersion objective lenses (Olympus, Tokyo,
Japan). Fluorescent images were obtained by a digital camera and
analyzed with Fluoview software (Olympus).

Immunoblotting and Coimmunoprecipitation

HUVECs were lysed with cold lysis buffer.28,29 After homogenization
and centrifugation, the supernatant was collected. For immunoblotting,
proteins were separated on SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were then incubated with primary antibodies and horseradish peroxidase-conjugated secondary antibody.
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The blot was developed with a Supersignal Chemiluminescence detection kit (Pierce, Rockford, IL). Bands were visualized by a Kodak
Image Station 4000R Pro (Rochester, NY). For coimmunoprecipitation, cell lysates were precleared with corresponding nonimmune IgG
and incubated together with protein A plus-Sepharose for 30 minutes at 4°C. Cleaned lysates were then incubated with 2 μg of either
anti-Cav1 or anti-nCDase antibodies. Cell lysates were then incubated with protein A plus-Sepharose overnight at 4°C. Nonimmune rabbit IgG served as negative control. Protein A beads were then washed
extensively with lysis buffer. Proteins were eluted from beads and
resolved by elusion buffer. Samples with 2×SDS sample buffer were
heated and separated by electrophoresis. After transfer to polyvinylidene fluoride membranes, proteins were immunoblotted with antiAdipoR1 (for Cav1/AdipoR1 interaction) or anti-Cav1 (for Cav1/
ceramidase interaction) as described above.

Intravital Microscopy Analysis of Leukocyte
Rolling and Adhesion

Leukocyte rolling and adhesion were assayed in mesenteric postcapillary venules by intravital microscopy as we previously described.30 In brief, mice were pretreated with gAPN (first dose:
1.0 μg/g, IP, 24 hours before TNFα administration; second dose:
1 μg/g, IP). Thirty minutes after the second dose of adiponectin,
mice were treated with recombinant TNFα (1.0 μg/kg, IP) for 2
hours. After exteriorization of a loop of ileum tissue via a midline laparotomy, the ileum was placed in a temperature-controlled
fluid-filled Plexiglas chamber and transilluminated for bright-field
observation of the peri-intestinal microcirculation. The ileum and
mesentery were perfused throughout the experiment with a buffered
K-H solution (pH 7.4; 37°C). Three to 4 straight, unbranched segments of postcapillary venules with lengths of >100 μm and diameters between 25 and 40 μm were studied in each mouse using an
Eclipse FN1 Microscope (Nikon Corp), and the image was recorded
and analyzed on A WIN XP Imaging Workstation. Leukocyte rolling was defined as the number of leukocytes rolling past a fixed
point per minute; leukocyte adherence was defined as the number
of leukocytes firmly adhered to 100-μm length of endothelium for
≥30 seconds. Rolling and adhesion were measured 4 hours after
TNFα injection. Venular blood velocity (V) was measured using the
Microvessel Velocity OD-RT optical Doppler velocimeter (Circusoft
Instrumentation) with corresponding software. Venular wall shear
rate (γ) was calculated using the formula: γ=4.9×8(Vmean/D), where
D is the venule diameter.

Statistical Analysis

All values in the text and figures are presented as mean±SEM of n
independent experiments. All data (except Western blot density) were
subjected to ANOVA followed by Tukey correction for post hoc t test.
Western blot densities were analyzed by the Kruskal–Wallis test followed by Dunn’s post hoc test. Probabilities of ≤0.05 were considered statistically significant.

Results
Anti-Inflammatory, Antioxidative, and
Antinitrative Effects of Adiponectin Are
Mediated Largely by AdipoR1
Treatment of HUVEC with TNFα elicits significant inflammatory response31 as evidenced by upregulated ICAM-1 expression (Figure 1), amplified superoxide generation, and
increased nitrotyrosine formation (Figure 2). Consistent
with previous reports, treatment with gAPN significantly
inhibited TNFα-induced ICAM-1 expression (Figure 1B),
inhibited superoxide generation (Figure 2A), and decreased
nitrotyrosine formation (Figure 2C). To identify the receptor subtype(s) responsible for gAPN’s aforementioned anti-
inflammatory actions, expression of AdipoR1 and AdipoR2
were genetically inhibited by siRNA (Figure 1A). Consistent

with previous reports, expression level of AdipoR1 is
higher than AdipoR2 in HUVEC (relative mRNA abundance [normalized against GAPDH]: AdipoR1=0.67±0.04;
AdipoR2=0.31±0.03; P<0.01). This expression patter is
not altered by acute TNFα treatment (AdipoR1=0.64±0.03;
AdipoR2=0.29±0.02; P>0.1 versus vehicle-treated group).
AdipoR1-knockdown (KD) slightly increased TNFαinduced ICAM-1 expression (Figure 1C) and superoxide
generation (Figures 2B; P>0.05) and significantly increased
nitrotyrosine formation (2.01±0.24 versus 3.36±0.48 pmol/
mg protein; P<0.05). AdipoR2-KD did not significantly
modify the TNFα-induced inflammatory reaction without
adiponectin treatment (Figure 1D). Most importantly, in
AdipoR1-KD HUVEC, the inhibitory effects of gAPN on
ICAM-1 expression (Figure 1C), superoxide generation
(Figure 2B), and nitrotyrosine formation (Figure 2D) were
all markedly (>87%) inhibited. In contrast, in AdipoR2-KD
HUVEC, the anti-inflammatory (Figure 1D), antioxidative
(Figure 2C), and antinitrative effects (Figure 2F) of gAPN
were largely retained. In a separate experiment, the influence
of AdipoR1-KD and AdipoR2-KD on the anti-inflammatory
effects of fAPN was determined. The fAPN did not inhibit
TNFα-induced inflammation as potently as gAPN (10 μg/
mL fAPN achieved comparable inhibitory effect as 2 μg/mL
gAPN and further increasing fAPN up to 20 μg/mL failed
to achieve better inhibitory effect; Figure 1B). The anti-inflammatory effect of fAPN (ICAM-1 expression presented in
Figure 1 and oxidative/nitrative stress presented in Figure 2)
was blocked largely by AdipoR1-KD (>76% inhibition;
P>0.05 versus TNFα with vehicle; Figure 1C) and blocked
modestly by AdipoR2-KD (<31% inhibition; P<0.05 versus
TNFα with vehicle; Figure 1D). These results demonstrate
that AdipoR1 largely mediates the anti-inflammatory effect
of adiponectin in HUVEC.

Activation of nCDase by gAPN Contributes to Its
Anti-Inflammatory Action
A recent study demonstrates that adiponectin activates nCDase, increasing its catalytic activity in several cell types, including β-cells, human embryonic kidney 239 cells, and liver
cells. This effect is blocked in AdipoR1 and AdipoR2 double
knockout (KO) cells.15 In HUVEC cells, neither TNFα nor
adiponectin (gAPN and fAPN) exhibited significant effect
on nCDase expression (Figure 3A). The ceramidase activation by gAPN is abolished virtually in AdipoR1-KD cells
and preserved in AdipoR2-KD cells, indicating that gAPN
increases nCDase activity in an AdipoR1-dependent fashion (Figures 3B). The ceramidase activity of fAPN is partially lost in AdipoR1 and AdipoR2-KD cells, with modestly
stronger inhibitory effect when AdipoR1 is genetically inhibited, a results constant with recent report in liver cells
(Figure 3B).15 To determine the role of nCDase activation in
adiponectin’s anti-inflammatory action, nCDase expression
was inhibited genetically by siRNA (Figure 3A, left, last
lane). As expected, adiponectin failed to increase nCDase
activity significantly in nCDase-KD HUVEC (Figure 3A,
right). Most importantly, KD of nCDase markedly, although
not completely, blocked the inhibitory effect of gAPN on
TNFα-induced ICAM-1 expression (Figure 3C).
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Figure 1. Effect of adiponectin receptor 1 (AdipoR1)/AdipoR2 knockdown on adiponectin (APN)’s anti–intercellular adhesion
molecule-1 (ICAM-1) effect. Human umbilical vein endothelial cells (HUVECs) were transfected with scramble or small interfering RNA
(siRNA) against AdipoR1/AdipoR2 to knockdown AdipoR expression (A). Forty-eight hours after transfection, cells were pretreated with
vehicle, globular adiponectin (gAPN) or full-length adiponectin (fAPN) followed by tumor necrosis factor (TNF)α treatment. Effect of APN
on TNFα-induced ICAM-1 expression (12 hours post-TNFα treatment) was determined in scramble (B), AdipoR1 siRNA (C), and AdipoR2
siRNA (D) transfected cells. *P<0.05, **P<0.01 vs TNFα-treated animals without APN treatment.

Role of AMPK in Adiponectin Activation of
nCDase and Anti-Inflammatory Action

Role of Cav1 in Adiponectin-Induced nCDase
Activation and Anti-Inflammatory Action

AMPK is a well-recognized downstream signaling molecule
of adiponectin.32 To determine the relationship between AMPK
and nCDase in relation to adiponectin’s anti-inflammatory
action, AMPK expression was inhibited genetically by siRNA (Figure 4A). As summarized in Figure 4B, transfection
with siRNA against AMPKα successfully blocked AMPK-
mediated acetyl-CoA carboxylase phosphorylation after
adiponectin treatment. However, AMPK-KD had no effect
on gAPN-induced nCDase activation (Figure 4C). Finally,
AMPK-KD partially blocked the effect of gAPN on TNFαinduced ICAM-1 expression (Figure 4D). These results
demonstrate that adiponectin activates nCDase in an AMPKindependent manner, but its anti-inflammatory effect is partially mediated by AMPK signaling.

We recently demonstrated that, by holding AdipoR1 and its
downstream signaling molecules in close proximity, forming a caveolae-located adiponectin signalsome, Cav3 (the
primary caveolin isotype expressed in cardiomyocytes) plays
an essential role in adiponectin’s cardioprotective actions
post myocardial ischemia/reperfusion.33 To clarify whether
Cav1 (the primary caveolin isotype expressed in endothelial
cells)34,35 is required for adiponectin activation of nCDase and
anti-inflammatory action in HUVEC, Cav1 expression was
downregulated by siRNA (Figure 5A, left). As summarized
in Figure 5, Cav1-KD not only blocked adiponectin activation
of nCDase activity (Figure 5A, right) but also virtually abolished the inhibitory effect of adiponectin on TNFα-induced
ICAM-1 expression (Figure 5B). To obtain more evidence
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Figure 2. Effect of adiponectin receptor 1 (AdipoR1)/AdipoR2 knockdown on adiponectin (APN)’s antioxidative and antinitrative
effect. Cells were treated as described in Figure 1. Effect of APN on tumor necrosis factor (TNF)α–induced superoxide production and
nitrotyrosine formation was determined in scramble (A and D), AdipoR1 (B and E), and AdipoR2 (C and F) transfected cells. *P<0.05,
**P<0.01 vs TNFα-treated animals without APN treatment. fAPN indicates full-length adiponectin; and gAPN, globular adiponectin.

that adiponectin activates nCDase and inhibits inflammatory
response in a Cav1-dependent manner, the effect of S1P and
SEW2871 (a selective S1P receptor 1 agonist) on TNFα-
induced ICAM-1 expression was compared in wild-type (WT)
and Cav1-KD cells. As summarized in Figure 5C, treatment
with either S1P or SEW2871 significantly inhibited TNFαinduced ICAM-1 expression, and their anti-inflammatory action was not blocked by Cav1-KD. These results demonstrate
that direct application of S1P, the end catalytic product of the
CDase system, bypasses Cav1-dependent nCDase activation
and remains effective in blocking TNFα-induced inflammatory action. This result also supports the necessity of Cav1
for certain (such as AdipoR1 and insulin receptor) but not all
membrane receptor-mediated signaling.

Cav1 Interacts With AdipoR1 and nCDase, Forming
a Signaling Complex
Results presented in Figures 3B and 5A demonstrated that
adiponectin increases nCDase activity in an AdipoR1 and
Cav1-dependent fashion. To determine whether the effect of
adiponectin on cellular levels of ceramide and S1P is also
AdipoR1/Cav1 dependent, additional experiment was performed. As illustrated in Figure 6A and 6B, treatment with
adiponectin significantly attenuated TNFα-induced ceramide
accumulation and increased S1P level, particularly at cellular membrane. These effects were virtually abolished when
either AdipoR1 or Cav1 expression was genetically inhibited, but largely preserved when AdipoR2 expression was
genetically inhibited.
Cav1 regulates transmembrane signaling largely via engagement of protein–protein interaction, facilitated by the

scaffold domain located within Cav1 and the caveolin binding motif located within its partner proteins.36 In a final attempt to clarify how Cav1 enables gAPN-initiated nCDase
activation, 2 series of experiments were performed. First,
the interaction between Cav1 and AdipoR1 was determined
by immunofluorescent microscopy and coimmunoprecipitation. As illustrated in Figure 6C, colocalization of Cav1
and AdipoR1 was clearly observed (top). Cav1-KD did not
alter AdipoR1 membrane localization (Figure 6C, bottom).
Cav1 and AdipoR1 were coimmunoprecipitated in HUVEC
(Figure 6D) and rat aortic endothelial cells (Figure 6E).
Treatment with adiponectin had no significant effect on this
protein–protein interaction (Figure 6D and 6E). Moreover,
re-expression of WT Cav1 in Cav1-KD cells restored Cav1/
AdipoR1 interaction (Figure 6D and 6E, right, first lane).
However, re-expression in Cav1-KD cells of a mutated
Cav1, in which 5 aromatic residues within the scaffolding
domain responsible for Cav1 interaction with partner proteins were converted to alanine,37 did not reestablish Cav1/
AdipoR1 interaction (Figure 6D and 6E, right, second lane).
Moreover, Cav1/nCDase interaction was also observed in
aortic segment from mice treated with vehicle or gAPN
(Figure 6F). Finally, coimmunoprecipitation identified
adiponectin /Cav1 interaction, indicating that adiponectin
binds the proposed Cav1/AdipoR1 complex (Figure 6G, upper). These results support basal Cav1/AdipoR1 interaction,
a protein–protein interaction requisite for adiponectin activation of nCDase.
In a separate experiment, potential Cav1/AdipoR2 interaction was determined by coimmunoprecipitation. As illustrated
in Figure 6G (lower), interaction between Cav1/AdipoR2 is
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Figure 3. Adiponectin receptor 1 (AdipoR1)-dependent neutral ceramidase (nCDase) activation mediates adiponectin (APN)
anti-inflammatory action. A, Transfection of human umbilical vein endothelial cells reduced nCDase expression (left) and blocked
nCDase activation by APN (right). B, Effect of AdipoR1 and AdipoR2 knockdown on APN-induced nCDase activation. C, Effect of
nCDase knockdown on the inhibitory action of APN on tumor necrosis factor (TNF)α–induced intercellular adhesion molecule-1 (ICAM-1)
expression. **P<0.01 vs Con (A and B). *P<0.05, **P<0.01 vs TNFα-treated animals without APN treatment (C). fAPN indicates full-length
adiponectin; and gAPN, globular adiponectin.

weak. The precise mechanisms responsible for the preferential
interaction between Cav1 and AdipoR1 over AdipoR2 remain
unclear at the present time. One possible explanation is that
AdipoR1 contains 2 caveolin binding motifs, of which one
is located within its cytosolic region, whereas AdipoR2 contains only 1 caveolin binding motif, which is located within
the transmembrane domain.

In second series of experiments, the interaction between
Cav1 and nCDase was determined. Under basal conditions
(vehicle), nCDase colocalization of Cav1 and nCDase is not
robustly apparent (Figure 7A), and coimmunoprecipitation
of Cav1 and nCDase is weak (Figure 7A). However, gAPN
treatment significantly increased Cav1/nCDase interaction,
as evidenced by clear colocalization (Figure 7A) and strong
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Figure 4. Role of AMP-activated protein kinase (AMPK) in adiponectin (APN)-induced neutral ceramidase (nCDase) activation.
Transfection of human umbilical vein endothelial cells with AMPKα small interfering RNA (siRNA) reduced AMPKα expression (A)
and blocked globular adiponectin (gAPN)–induced acetyl-CoA carboxylase (ACC) phosphorylation (pACC; B). In contrast, APNinduced nCDase activation was not affected (C) and APN’s anti–tumor necrosis factor (TNF)α (intercellular adhesion molecule-1
[ICAM-1] expression, D) was only partially inhibited when AMPK expression was genetically inhibited. *P<0.05, **P<0.01 vs respective
control (Con).

coimmunoprecipitation (Figure 7B and 7C). Although the
weak basal Cav1/nCDase interaction is not affected by
AdipoR1-KD, the adiponectin-stimulated enhancement of
Cav1/nCDase interaction is inhibited in AdipoR1-KD cells,
but not altered in AdipoR2-KD cells (Figure 7B). The interaction pattern between Cav1/nCDase clearly differs from
Cav1/AdipoR1. Specifically, strong Cav1/AdipoR1 interaction is observed during basal conditions but is not regulated
by adiponectin. In contrast, basal Cav1/nCDase interaction
is weak and is markedly enhanced after adiponectin treatment. These results suggest that AdipoR1–Cav1–nCDase
forms a complex and their association is enhanced after
adiponectin treatment. To obtain more evidence supporting
this notion, AdipoR1/nCDase interaction in the presence
and absence of adiponectin was determined. As illustrated in Figure 7D, weak AdipoR1/nCDase interaction was

observed and treatment with adiponectin significantly enhanced interaction.

Inhibitory Effect of Adiponectin on Leukocyte
Rolling and Adhesion Is AdipoR1 and Cav1
Dependent
To validate in vitro finding in a pathologically relevant in
vivo model, interaction of Cav1 and nCDase and effect of
AdipoR1/AdipoR2 and Cav1-KO on adiponectin inhibition
of TNFα-induced leukocyte rolling and adhesion was determined using intravital microscopy. As illustrated in Figure 6E,
Cav1/nCDase interaction and its enhancement were observed
in aortic tissues from animals treated with vehicle or gAPN.
Consistent with our previous report,30 in vivo treatment of WT
mice with gAPN significantly inhibited TNFα-induced leukocyte rolling and adhesion (Figure 8). Cav1-KO only slightly
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Figure 5. Role of caveolin-1 (Cav1) in adiponectin (APN)-induced neutral ceramidase (nCDase) activation and anti-inflammatory
action. Human umbilical vein endothelial cell Cav1 expression was genetically inhibited by Cav1 small interfering RNA (siRNA; A, left).
Cav1 knockdown (KD) blocked APN-induced nCDase activation (A, right) and anti-inflammatory effects of APN (intercellular adhesion
molecule-1 [ICAM-1] expression, B). However, Cav1-KD had no significant effect on anti-inflammatory effects of sphingosine-1phosphate (S1P) and a selective S1P receptor 1 agonist (SEW2871; C). **P<0.01 vs respective control (A) or vs tumor necrosis factor
(TNF)α–treated animals without APN treatment (B and C). fAPN indicates full-length adiponectin; and gAPN, globular adiponectin.
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Figure 6. Effect of adiponectin receptor 1 (AdipoR1)/AdipoR2 or caveolin-1 (Cav1) knockdown (KD) on cellular levels of
ceramide (A) and sphingosine-1-phosphate (S1P; B) after tumor necrosis factor (TNF)α treatment in the presence and absence
of globular adiponectin (gAPN). Representative photos from ≥5 repeated experiments. C, Cav1/AdipoR1 colocalization determined
by immunofluorescent staining. Representative photos from ≥5 repeated experiments. D, Cav1/AdipoR1 interaction determined by
coimmunoprecipitation in human umbilical vein endothelial cells (HUVECs). Cav1 was immunoprecipitated with antibody against Cav1
and samples were immunoblotted with antibody against AdipoR1 (upper). To immunoprecipitate AdipoR1, HUVECs were transfected
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Figure 6 (Continued). with Myc-tagged AdipoR1 expressing vector and immunoprecipitated with antibody against Myc. Samples were
then immunoblotted with antibody against Cav1 (lower). E, Cav1/AdipoR1 interaction determined by coimmunoprecipitation in rat aortic
endothelial cells (RAECs). Re-expression in Cav1-KD cells of a mutated Cav1 (MUT), in which 5 aromatic residues within the scaffolding
domain responsible for Cav1 interaction with partner proteins were converted to alanine. F, Cav1/nCDase interaction determined by
coimmunoprecipitation in aortic segment from mice treated with vehicle or gAPN. Representative blots from ≥5 repeated experiments.
G, APN/Cav1 complex forming (upper) and lack of AdipoR2/Cav1 interaction determined by immunoprecipitation (lower). Representative
blots from ≥5 repeated experiments. IB indicates immunoblotting; WT, wild-type.

(P>0.05) increased leukocyte rolling and adhesion after TNFα
treatment, likely because of the increased basal nitric oxide
production in these animals. In AdipoR1-KO mice, greater
leukocyte rolling and adhesion were observed after TNFα
treatment (P<0.05 versus WT). Most importantly, the inhibitory effect of adiponectin on TNFα-induced leukocyte rolling
and adhesion observed in WT mice was markedly inhibited
in AdipoR1-KO mice (Figure 8) and completely abolished
in Cav1-KO mice (leukocyte rolling, 45±3.3 cells/100 μm
with adiponectin treatment versus 48±3.8 cells/100 μm with
vehicle, P>0.1; leukocyte adhesion, 6.4±0.4 cells/100 μm
with adiponectin versus 6.6±0.5 cells/100 μm with vehicle,
P>0.1). Moreover, opposite from those results observed in
AdipoR1-KO mice, the inhibitory effect of adiponectin on
TNFα-induced leukocyte rolling and adhesion was largely
preserved in AdipoR2-KO mice (Figure 8). Leukocyte rolling

was slightly decreased in AdipoR2-KO mice compared with
AdipoR1-KO mice during basal conditions (before TNFα
challenge), without statistically significant difference. This
result is consistent with previous observations that no significant phenotype manifests in adiponectin-KO mice, unless
challenged by metabolic or inflammatory stress.

Discussion
We have made 3 novel observations in this study. First, we
demonstrate that the anti-inflammatory (determined by
ICAM-1 expression), antioxidative (determined by superoxide production), and antinitrative (determined by nitrotyrosine
formation) actions of gAPN are largely mediated by AdipoR1.
At least 3 possibilities potentially explaining the superior function of AdipoR1 over AdipoR2 in the vascular system exist. It
has been demonstrated previously that AdipoR1 has greater

A

B

C

D

Figure 7. Cellular distribution of
neutral ceramidase (nCDase)
without adiponectin (APN)
treatment (A, top) and effect of
APN treatment on caveolin-1
(Cav1) and nCDase interaction
in wild-type (WT), Cav1-KD, or
AdipoR1-KD human umbilical
vein endothelial cells (HUVECs;
A, confocal microscopy; B,
immunoprecipitation). Note that
APN-enhanced Cav1/nCDase
interaction is blocked by AdipoR1,
but not AdipoR2 knockdown.
Cav1/AdipoR1/nCDase complex
formation determined by
immunoprecipitation (C and
D). Representative images
from ≥5 repeated experiments/
experimental conditions. gAPN
indicates globular adiponectin.
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Figure 8. Effect of adiponectin receptor 1 (AdipoR1)/AdipoR2 knockout (KO) on adiponectin (APN) inhibition of tumor necrosis
factor (TNF)α-induced leukocyte rolling and adhesion. Wild-type (WT), AdipoR1-KO, and AdipoR2-KO mice were pretreated with
vehicle or globular adiponectin and leukocyte rolling and adhesion were observed using intravital microscopy after TNFα injection. The
inhibitory effect of APN on TNFα-induced leukocyte rolling (A) and adhesion (B) observed in WT mice was virtually abolished in AdipoR1
but not in AdipoR2-KO mice. No significant difference was observed in mean arterial blood pressure (MABP) among different treatment
group (C). **P<0.01 vs TNFα-treated animals without APN treatment; #P<0.05, ##P<0.01 vs WT with the same treatment.

gAPN binding affinity than AdipoR2.38,39 However, our results
indicating fAPN (which has comparable binding affinity to
both AdipoR1 and AdipoR2) exhibits an anti-inflammatory effect with stronger dependency on AdipoR1 argues against this
possibility. A more likely explanation concerns prevalence.
As AdipoR1 is the dominant adiponectin receptor isotype expressed in vascular tissue,39 it stands to reason AdipoR1 would
be chiefly responsible for the biological effects of adiponectin within the vascular system. Another possibility involves
isotype-specific intracellular signaling. It is well recognized
that membrane receptors possessing multiple subtypes (such

as TNFα and β-adrenergic receptors) initiate different or
even opposite intracellular signaling through different subtype activation. It is thus possible that AdipoR1 and AdipoR2
may activate different intracellular signaling pathways, with
anti-inflammatory, antioxidative, and antinitrative signaling
preferentially mediated by AdipoR1. Regardless of which
possibility is true, the current study strongly suggests that although interventions activating AdipoR2 may better regulate
hepatic metabolism, molecules strongly activating AdipoR1
(such as the globular domain of adiponectin) may have greater therapeutic efficacy reducing vascular injury, particularly
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from inflammatory changes. This conclusion is further supported by our previous study demonstrating that increased
cardiomyocyte adiponectin production and resultant cardiac
protection as a result of rosiglitazone treatment are primarily
mediated by AdipoR1 activation.40
Second, we demonstrate that gAPN activates HUVEC nCDase in an AMPK-independent fashion and nCDase activation
significantly contributes to adiponectin’s anti-inflammatory
function. In recent years, the biological activities of adiponectin have been investigated extensively. Four major functions (including metabolism-regulatory, anti-inflammatory,
vasculoprotective, and cardioprotective effects) have been
identified.41 Among multiple intracellular molecules activated
after adiponectin binding of its specific membrane receptors,
AMPK is the molecule most intensively investigated and is
generally accepted as the most important intracellular signaling molecule mediating adiponectin biological functions.32
However, accumulating evidence suggests that the degree of
AMPK involvement in biological regulation of adiponectin is
dependent on organ and disease.42 Specifically, pharmacological inhibition of AMPK activity or genetic inhibition of AMPK
expression virtually abolishes the central metabolic actions
of adiponectin,43,44 indicating that AMPK plays an essential
role in hepatic metabolic regulation of adiponectin. However,
we13 and others45 have demonstrated recently that the anti-
ischemic/cardioprotective effects of adiponectin are largely
AMPK-independent and involve the cyclooxygenase-2 and
nuclear factor κB–mediated signaling pathways. Moreover, a
recent elegant study reported that adiponectin exerts antiapoptotic and cellular protective actions in an AMPK-independent,
nCDase-dependent manner.15 Our current study demonstrates
that unlike adiponectin’s metabolic and antiapoptotic actions
(largely AMPK-dependent or largely AMPK-independent),
adiponectin’s anti-inflammatory function is mediated by
both the traditional AMPK pathway and the newly identified
AMPK-independent nCDase activation pathway.
Third, and most importantly, we provide the first direct evidence that Cav1 plays an essential role in AdipoR1-mediated
nCDase activation and the anti-inflammatory actions of adiponectin. At least 2 possibilities exist that may explain the
necessity of Cav1 in adiponectin vascular signaling. First, as
suggested by a recent experimental study, AdipoR1 may exert
nCDase activity and catalyze the ceramide reaction. Because
many cofactors required for enzymatic reactions enrich in
caveolae, Cav1 loss may destroy the local environment optimized for nCDase catalytic reactions. The second and more
likely explanation is that binding of adiponectin to AdipoR1
recruits nCDase to the Cav1/AdipoR1 complex, facilitating
their activation. This possibility is supported by the following
4 experimental evidences: (1) Cav1 colocalizes and coimmunoprecipitates with AdipoR1, suggesting that these 2 proteins
interact with each other; (2) mutation of 5 aromatic residues
within the scaffolding domain known to be responsible for
Cav1 interaction with its partner proteins not only inhibited
Cav1/AdipoR1 interaction, but also blocked adiponectin activation of nCDase; (3) Cav1 interacts with nCDase in a different
fashion than AdipoR1. Whereas the Cav1/AdipoR1 interaction seems static, the Cav1/nCDase interface is dynamically
regulated in an AdipoR1-dependent fashion; and (4) treatment

with adiponectin significantly brought Cav1/nCDase in closer
proximity to each other. Combs et al46 previously reported
that mice overexpressing adiponectin displays elevated Cav1
levels in adipocyte and that Cav1-KO significantly reduces
plasma adiponectin levels.47 Collectively, currently available
experimental evidence supports that Cav1 plays essential roles
in adiponectin production as well as adiponectin transmembrane signaling.
Cav1 is an essential molecule in EC caveolae formation.
The role of Cav1 in atherosclerosis development is extremely
complex. Either pro- and antiatherosclerotic effects have been
reported, depending on cell types and disease development
stage investigated.36,48 Although the dark mechanisms of Cav1
promoting atherosclerosis have been investigated extensively,
the bright side mechanisms of Cav1 preventing atherosclerosis remain largely unknown. Our current experiments demonstrated that Cav1 interacts with AdipoR1, facilitating nCDase
recruitment/activation on adiponectin binding, enabling the
anti-inflammatory signaling of adiponectin.
Two limitations exist in the current study. First, we have
provided clear evidence that adiponectin activation of
AdipoR1 increases nCDase interaction with Cav1. However,
how activation of AdipoR1 by adiponectin increases Cav1/
nCDase interaction remains unclear. Because AdipoR1 directly interacts with Cav1, it is possible that adiponectin binding to AdipoR1 may promote Cav1 conformational change
as that caused by other Cav1 interacting molecule,49 thus increasing its affinity with nCDase. This intriguing possibility
will be deeply investigated in our future studies. Second, we
have demonstrated that the anti-inflammatory/antioxidative/
antinitrative actions of adiponectin are largely mediated by
AdipoR1, not AdipoR2. In addition to these 2 evolutionarily
acquired specific receptors, other cell surface binding proteins (such as T-cadherin) tether high molecular weight isoforms of adiponectin to the cell surface, possibly facilitating
adiponectin/AdipoR interaction.50 The role of these proteins in
adiponectin’s anti-inflammatory and vasculoprotective actions
warrants future investigation.
In summary, we demonstrate for the first time that adiponectin inhibits TNFα-induced inflammatory response via
Cav1-mediated ceramidase recruitment and activation in an
AdipoR1-dependent fashion. These experimental results not
only deepen our understanding of adiponectin biological signaling, but also suggest interventions facilitating AdipoR1/
Cav1/nCDase signaling (such as upregulating AdipoR1 expression and stimulating nCDase) may be novel vasculoprotective targets in the patient with diabetes mellitus.
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Novelty and Significance
What Is Known?
• Type 2 diabetes mellitus affects >20 million people in the United States
and is a major risk factor for cardiovascular diseases.
• Adiponectin (APN), produced by adipocytes, protects against cardiovascular injury from inflammation, through interaction with one or both
of its receptor proteins (AdipoR1 or AdipoR2).
• Adiponectin has been shown to decrease inflammation by activating
ceramidase. It is, however, unknown whether adiponectin protects
against vascular injury from inflammation by activating ceramidase or
if AdipoR1/AdipoR2 themselves function as ceramidases.

What New Information Does This Article Contribute?
• Adiponectin decreases inflammation primarily through AdipoR1.
• The activation of ceramidase significantly contributes to adiponectin’s
anti-inflammatory function.
• The cell-signaling carrier protein caveolin-1 is essential for AdipoR1mediated ceramidase activation and the resultant anti-inflammatory
actions of adiponectin.

individuals. Inflammation plays a major role in the cardiovascular complications of diabetes mellitus. Adiponectin is known to
protect against cardiovascular injury caused by inflammation,
through interaction with one or both of its receptor proteins
(AdipoR1 and AdipoR2). It has been shown that adiponectin
decreases inflammation through the enzyme ceramidase; however, it remains unknown whether adiponectin protects against
vascular injury from inflammation by activating ceramidase or if
AdipoR1/AdipoR2 themselves function as ceramidases. Here, we
show that adiponectin decreases inflammation primarily through
AdipoR1. Ceramidase activation significantly contributes to the
anti-inflammatory effects of adiponectin. We demonstrate the necessity of caveolin 1 for AdipoR1-mediated ceramidase activation
and the resultant anti-inflammatory actions of adiponectin. Our
work contributes to a better understanding of adiponectin biological signaling. Furthermore, these findings provide the framework
for new approaches (such as increasing AdipoR1 protein expression or stimulation ceramidase activity) to decrease vascular injury in patients with diabetes mellitus.

Patients with both type 1 and type 2 diabetes mellitus experienced more cardiovascular effects of inflammation than healthy

Downloaded from http://circres.ahajournals.org/ at Thomas Jefferson Universi on October 12, 2014

Supplemental Material

Adiponectin inhibits TNF-α-induced vascular inflammatory response via caveolin-mediated
ceramidase recruitment and activation

Wang et al. APN in vascular inflammation

Yajing Wang, MD, PhD1*, Xiaoliang Wang, MD, PhD1, Wayne Bond Lau, MD1,
Yuexin Yuan, PhD1, David Booth, PhD2, Jing-Jing Li, BS1, Rosario Scalia, MD, PhD3,
Kyle Preston, BS3, Erhe Gao, MD, PhD4, Walter Koch, PhD4, Xin-Liang Ma, MD, PhD1*

SUPPLEMENTAL METHODS

Materials
Human umbilical vein endothelial cells (HUVEC), rat aortic endothelial cells (RAEC) and cell
culture reagents were purchased from Cell Applications (San Diego, CA). Fetal bovine serum
was from Hyclone (Logan, CT). Antibody against caveolin-1 (Cav1), Pan-cadherin and Cy5conjugated secondary antibody were from Abcam. Antibodies against ICAM-1, ACC,
phosphorylated ACC, and FITC, tetramethyl rhodamine (TRITC)-conjugated or horseradish
peroxidase-conjugated secondary antibodies were from Cell Signaling Technology (Danvers,
MA). Antibodies against AdipoR1 and AdipoR2 were from Bioss Inc (Woburn, MA).
Antibodies against Ceramide and S1P were from Sigma (Saint Louis, MO) and Novus
Biologicals (Littleton, CO). Recombinant human TNF-α protein (rhTNFα) and nCDase antibody
were from R&D System (Minneapolis, MN). Recombinant human globular and full length APN
(gAPN and fAPN) were from Peprotech, Inc (Rocky Hill, NJ). S1P and SEW2871 (a selective
S1P receptor-1 agonist21) were from Cayman Chemical (Ann Arbor, MI). S1P was dissolved in
70% ethanol. A stock solution for S1P was then made in 1% fatty acid–free bovine serum (FBS)
albumin in PBS (137 mmol/L sodium chloride, 1.5 mmol/L potassium phosphate, 7.2 mmol/L
sodium phosphate, 2.7 mmol/L potassium chloride, pH 7.4). An appropriate amount of the stock
solution was then added to the cultured cells to yield the desired final concentration of S1P.
Cell Culture and Treatments
HUVEC (Passage 2-3) were plated on six-well plates and cultured in endothelial growth medium
containing 10% fatal bovine serum, 2mM glutamine, 100U/ml penicillin, and 100 μg/ml
streptomycin at 37°C and 5% CO2. Upon 80% confluence, cells were treated with vehicle, gAPN
(2 µg/ml14) or fAPN (10 µg/ml). One hour after APN treatment, 10 ng/ml rhTNFα22 was added.
Cells were collected 12 hours after TNFα treatment and oxidative/nitrative stress and ICAM-1
expression were determined as described in detail below.
Small Interfering RNA Transfection, Plasmid Construction, and Transfection
siRNA duplexes against Cav-123, AdipoR124, AdipoR224, AMPKα124, and nCDase25 were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Universal control oligonucleotides
(AllStars) from Santa Cruz served as negative control. HUVECs (80% confluent) were
transfected via siIMPORTER siRNA transfection kit (Qiagen Science Inc. Benelux) per
manufacturer’s protocol (final siRNA concentration: 50 nM). The cells were then incubated at
37°C with mixture of transfection regent and siRNA. After 5 hours, the cells in each well were
replaced with fresh growth medium. At 72 hours after transfection, the cells transfected with
control and experimental siRNA were used for experiments, harvested separately for extraction
of total protein, and used for Western blot analysis or Immunoprecitipation assay. For plasmid
construction, the cDNA encoding full-length (FL) human Cav-1 and muCav-1 were subcloned
into pcDNA3.1 at Hind III and XbaI sites. The FL constructs then served as templates to further
generate scaffolding domain alanine mutants (muCav-1) using standard PCR-based strategies.
Scaffolding domain alanine region: DGIWKASFTTFTVTKYWFYR; Alanine mutagenesis
region:DGIWKASATTAAVTKYAAYR. Endothelial cells were maintained in culture with 10%
fetal bovine serum DMEM medium (Cell Applications, CA). For most experiments, cells in a

60-mm culture plate were transfected with 2μg of plasmid DNA encoding muCav-1, FLCav-1,
using LipofectAMINE (Qiagen) according to the manufacturer’s protocols. When cells were cotransfected with plasmid DNA, empty vector (no cDNA insert) was used as control.
Approximately 4 hours after transfection, culture medium was switched to 10% DMEM culture
medium and incubation proceeded for 48 hours prior to the experiments. Then the cells will be
harvested for extraction of total protein and used for the following experiments.
Ceramidase Enzyme Activity Assay
The nCDase enzyme activity was determined as previously reported, with minor modification26.
Briefly, at experiment conclusion, cells were collected and washed twice with PBS. Cell pellets
were resuspended in 100 μl 0.25 M sucrose solution, sonicated, and centrifuged at 15,000 g for 3
minutes. The supernatant was collected and protein concentration was determined. A 25 μl
sample containing identical protein amount, 75μl 25 mM phosphate buffer (pH 7.4), and 0.5 μl 4
mM Rbm14-12 substrate solution in ethanol (final substrate concentration 40 μM; final ethanol
concentration 1%) were loaded into each well of a 96-well plate. The same incubation mixture
without supernatant served as negative control. The plate was incubated at 37°C for 1 hour
without agitation. The enzymatic reaction was stopped by adding 25 μl methanol and 100 μl
NaIO4 (2.5 mg/ml) in 200 mM glycine/NaOH buffer (pH 10.6) to each well. The plate was
placed in a dark room for 1 hour. Fluorescent intensity was quantified via SpectraMax
Microplate Reader (Molecular Devices, λex 355 nm, λem 446 nm).
Determination of Superoxide and Peroxynitrite Content
Superoxide content was quantified by lucigenin enhanced luminescence, and the cellular origin
of reactive oxygen species was determined by dihydroethidium staining (DHE, Molecular Probes,
Carlsbad, CA). Briefly, histological detection of superoxide anion in situ was performed using
fresh-cultured endothelial cells stained with DHE (5µmol/L) in medium for 5 minutes at 37°C.
The intensity of the fluorescence signal was analyzed using IPlab Imaging Software 4.5
(BioVision, Rockingham, VT). Nitrotyrosine content, the footprint of peroxynitrite formation,
was quantified by a modified ELISA procedure. In brief, endothelial cells were homogenized in
ice cold PBS (1:10 w/v) using sonication with a dismembrator (Fisher Scientific, Pittsburgh, PA).
The homogenates were centrifuged for 10 min at 12,000g at 4°C. The supernatants were
collected and protein concentrations were determined by Bio-Rad method. A nitrated protein
solution was prepared for use as a standard by adding 8 μl of chemically synthesized ONOO−
(concentration: 100-120 mM) to 3 ml of 0.04% (0.4 mg/ml) BSA in PBS. The amount of
nitrotyrosine present in the peroxynitrite-treated BSA solution was measured at 430 nm using a
spectrophotometer (Beckman DU 640, Fullerton, CA) and expressed as nanograms per milliliter.
The stock solution of the peroxynitrite-treated BSA was diluted with PBS (final nitrotyrosine
concentration, 0.75–75 ng/ml). These standard samples, along with samples from endothelial
cells (protein concentration, 4 mg/ml) were applied to disposable sterile ELISA plates (Corning
Glassworks, Corning, NY) and allowed to bind for 1 h at 37°C in a microincubator shaker
(Teitec Co., San Jose, CA). After blocking nonspecific binding sites with 1% BSA in PBS, the
wells were incubated for 60 min at 37°C with a rabbit polyclonal anti-nitrotyrosine primary
antibody (Millipore) and subsequently for 60 min at 37°C with a peroxidase-conjugated goat
anti-rabbit IgG secondary antibody (1:1000, Amersham Pharmacia Biotech, Inc. Piscataway, NJ).
After washing the plates, the peroxidase reaction product was generated usingO-

phenylenediamine dihydrochloride (2.2 mM) (Abbott Diagnostics, Abbott Park, IL). The plate
was incubated for 20 min in the dark at room temperature, and the reaction was stopped by
addition of 20 ml of 2 M H2SO4. The optical density was measured at 460 nm with a SpectraMax
L microplate reader (MD LLC, Sunnyvale, CA). The amount of nitrotyrosine content in samples
was calculated using standard curves generated from nitrated BSA containing known amounts of
nitrotyrosine.
Confocal Immunofluorescence Microscopy
30 minutes after vehicle or gAPN treatment, HUVEC were fixed with 4%
paraformaldehyde/PBS in µ-Slide (ibidi LLC, Verona, WI) for 15 minutes followed by PBS
washing. Cells were first treated with antibodies against AdipoR1, Cav1, or nCDase (at 1:200),
followed by incubation with tetramethyl rhodamine (TRITC)-conjugated anti-rabbit IgG and
Cy5-conjugated anti-goat IgG (1:200). For Ceramide and S1P staining, cells were fixed with 4%
paraformaldehyde/PBA for 2 min. Cells were then washed with ddH2O (2 min) and TBS (pH7.6,
5 min). Nonspecific binding sites were blocked by 2x casein solution (Vector Inc.) for 10 min at
room temperature. The primary antibodies were prepared with TBS solution containing 5µM of
CaCl2 and cells were incubated with antibody for 2 h at room temperature. After 10 min washing
with TBS under agitation, cells were incubated with florescence labeled secondary antibody.
After washing with PBS, coverslips were mounted utilizing an anti-fade solution (KPL,
Gaithersburg, MD). Samples omitting the primary antibody served as negative control. Slides
were visualized by a FV1000 confocal microscope with x60 oil-immersion objective lenses
(Olympus, Tokyo, Japan). Fluorescent images were obtained by a digital camera and analyzed
with Fluoview software (Olympus).
Immunoblotting and Co-Immunoprecipitation
HUVECs or RAECs were lysed with cold lysis buffer [50 mM Tris-HCl, pH 7.4/100 mM
NaCl/0.1 mM EGTA/0.1 mM EDTA/1% Triton X-100/1 mM sodium orthovanadate/20 mM
NaF/1 mM Na4P2O7 and cocktail protease inhibitor; For Cav-1 immnoprecipitation, 10mM Tris,
pH 8.0/60 mM n-octyl β-D-glucopyranoside/150 mM NaCl/1 mM sodium orthovanadate/20 mM
NaF/1 mM Na4P2O7 and cocktail protease inhibitor]29, 30. After homogenization and
centrifugation, the supernatant was collected. For immunoblotting, proteins were separated on
SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were then incubated
with primary antibodies (anti-ICAM-1, anti-nCDase, anti-ACC, anti-pACC, anti-AdipoR1, antiCav1, and anti-GAPDH) and HRP-conjugated secondary antibody. The blot was developed with
a Supersignal Chemiluminescence detection kit (Pierce, Rockford, IL). Bands were visualized by
a Kodak Image Station 4000R Pro (Rochester, NY). For co-immunoprecipitation, cell lysates
were pre-cleared with corresponding nonimmune IgG, and incubated together with protein A
plus-Sepharose for 30 minutes at 4°C. Cleaned lysates were then incubated with 2 µg of either
anti-Cav1 or anti-nCDase antibodies. Cell lysates were then incubated with protein A plusSepharose overnight at 4°C. Nonimmune rabbit IgG served as negative control. Protein A beads
were then extensively washed with lysis buffer. Proteins were eluted from beads, and resolved by
elusion buffer. Samples with 2XSDS sample buffer were heated and separated by electrophoresis.
After transfer to PVDF membranes, proteins were immunoblotted with anti-AdipoR1 (for
Cav1/AdipoR1 interaction) or anti-Cav1 (for Cav1/ceramidase interaction) as described above.

Intravital Microscopy Analysis of Leukocyte Rolling and Adhesion
Leukocyte rolling and adhesion was assayed in mesenteric post-capillary venules by intravital
microscopy as we previously described31. In brief, mice were pretreated with gAPN (first dose:
1.0 µg/g, i.p., 24 hours before TNFα administration; second dose: 1 µg/g, i.p.). 30 min after the
second dose of APN, mice were treated with recombinant TNFα (1.0 µg/kg, i.p) for 2 hours.
Following exteriorization of a loop of ileum tissue via a midline laparotomy, the ileum was
placed in a temperature-controlled fluid-filled Plexiglas chamber and trans-illuminated for
bright-field observation of the peri-intestinal microcirculation. The ileum and mesentery were
perfused throughout the experiment with a buffered K-H solution (pH 7.4, 37°C). Three to four
straight, unbranched segments of post-capillary venules with lengths of >100 μm and diameters
between 25 and 40 μm were studied in each mouse using an Eclipse FN1 Microscope (Nikon
Corp), and the image recorded and analyzed on A WIN XP Imaging Workstation. Leukocyte
rolling was defined as the number of leukocytes rolling past a fixed point per minute; leukocyte
adherence was defined as the number of leukocytes firmly adhered to 100-μm length of
endothelium for at least 30 seconds. Rolling and adhesion were quantitated 4 hours following
TNF-α injection. Venular blood velocity (V) was measured using the Microvessel Velocity ODRT optical Doppler velocimeter (Circusoft Instrumentation) with corresponding software.
Venular wall shear rate (γ) was calculated using the formula: γ=4.9×8(Vmean /D), where D is
the venule diameter.

